50-10-2
50-10-2
Chemical Structure
Oxyphenonium bromide
- CAS No.: 50-10-2
- Formula:C21H34BrNO3
- Molecular Weight:428.40
IUPAC Name: 2-(2-cyclohexyl-2-hydroxy-2-phenylacetoxy)-N,N-diethyl-N-methylethan-1-aminium bromide
InChIKey: UKLQXHUGTKWPSR-UHFFFAOYSA-M
SMILES: O=C(OCC[N+](CC)(CC)C)C(O)(C1CCCCC1)C2=CC=CC=C2.[Br-]
Biological Activity: Oxyphenonium bromide is an antiacetylcholine compound. Oxyphenonium bromide is an antagonist of mAChR. Oxyphenonium bromide protects against the bronchial obstructive effects[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Oxyphenonium bromide | 99.39% | Oxyphenonium bromide is an antiacetylcholine compound. Oxyphenonium bromide is an antagonist of mAChR. Oxyphenonium bromide protects against the bronchial obstructive effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Oxyphenonium bromide (Standard) | ≥98% | Oxyphenonium (bromide) (Standard) is the analytical standard of Oxyphenonium (bromide). This product is intended for research and analytical applications. Oxyphenonium bromide is an antiacetylcholine compound. Oxyphenonium bromide is an antagonist of mAChR. Oxyphenonium bromide protects against the bronchial obstructive effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Funasaki N, et al. Quantitative estimation of the bitter taste intensity of oxyphenonium bromide reduced by cyclodextrins from electromotive force measurements. Anal Chem. 1999 May 1;71(9):1733-6. [Content Brief]
- [2]. Koëter GH, et al. Protective effect of oral oxyphenonium bromide, terbutaline and theophylline against the bronchial obstructive effects of inhaled histamine, acetylcholine and propranolol. Eur J Clin Pharmacol. 1984;26(4):435-41. [Content Brief]
- [3]. Eglen RM, et al. Competitive and non-competitive antagonism exhibited by 'selective' antagonists at atrial and ileal muscarinic receptor subtypes. Br J Pharmacol. 1987 Apr;90(4):701-7. [Content Brief]
